Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Andradi S.
Department of Neurology, University of Indonesia,
Jakarta, Indonesia
CURRICULUM VITAE
Nama : Dr ANDRADI SURYAMIHARJA SpS (K)
Pendidikan :
Pekerjaan :
• Anggota IDI
• Anggota/Pengurus PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia)
• Ketua Komisi Ujian Nasional, Kolegium Neurologi Indonesia
(sampai dengan tahun 2011)
• Anggota WFN ( World Federation of Neurology)
• Anggota ASNOS ( Asian Neuro-ophthalmology Society)
• Anggota / Anggota Pengurus Pokdi Nyeri, Pokdi Vertigo, Pokdi Stroke,
Pokdi Parkinson dan Movement Disorders
• Anggota/Pengurus Ikatan Keseminatan Kardioserebrovaskular Indonesia
(IKKI)
• Anggota AAN (American Academy of Neurology)
PARKINSON’S DISEASE:
CLINICAL DIAGNOSTIC CRITERIA
Parkinson’s Disease
Symptomatic
SYMPTOMATIC TREATMENT
I. MEDICAL
1. Pharmacologic
a. Dopaminergic agents
b. Cholinergic agents
c. Non-motor symptoms therapy
2. Non-pharmacologic
Education, self-help group, exercise, speech therapy
II. SURGICAL
1. Ablative / Lesioning
Thalamotomy, pallidectomy.
I. MEDICAL
1. Dopaminergic:
- L-Dopa/benserazide
- Dopamine agonist: oral bromocryptine, ropinirole,pramipexole, apomorphin,
patch rotigotine
- MAOB inhibitor: selegilline, rasagiline
- COMT inhibitor: entacapone, tolcapone.
- NMDA receptor antagonist: amantadine.
2. Cholinergic:
trihexyphenidyl.
BRAIN
Ganglia basalis
Dopamin Acetylcholin Normal
MAO MAO I ( selegiline )
Anticholinergic
Perokside Radical H (Trihexylphenidyl)
Dopamin Tissue
Receptor D2 Dopamin damage
Decarboxylase
Levodopa Acetylcholin PD
BLOOD BRAIN BARIER
Levodopa 3 OMD
COMT Inhibitor
COMT
Dopamin Agonist (entacapone)
Decarboxylase
Ergot
Decarboxylase Inhibitor
Non Ergot Dopamin
(bromocryptin) (pramipexole, (Benzeraside)
rotigotine) PERIFER (carbidopa)
PHARMACOLOGIC TREATMENT
Gangguan Fungsional
Ya Tidak
Terapi Neuroprotektif
Terapi simptomatik
Antioksidan
Tremor dominan ?
Ya Tidak
● Agents
Anticholinergic, DA agonist (oral, patch), amantadine, or MAOB-I.
● Benefit
- mild symptomatic control for 6-8 months
- less than L-Dopa